Jasper Therapeutics to Present at Cantor Fitzgerald's The Future of Oncology Virtual SymposiumGlobeNewsWire • 03/31/23
Jasper Therapeutics Appoints Daniel Adelman, M.D., as Acting Chief Medical OfficerGlobeNewsWire • 03/23/23
Jasper Therapeutics Reports Fiscal 2022 Financial Results and Provides a Business UpdateGlobeNewsWire • 03/08/23
Jasper Therapeutics Appoints Industry Veteran Vishal Kapoor to its Board of DirectorsGlobeNewsWire • 02/17/23
Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTRGlobeNewsWire • 02/17/23
Jasper Therapeutics Presents Data Supporting Ongoing Development of Briquilimab, its c-Kit Targeting Antibody, at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTRGlobeNewsWire • 02/17/23
Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Sickle Cell Disease PatientsGlobeNewsWire • 02/16/23
Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 02/03/23
Jasper Therapeutics to Host Investor Conference Call and Webcast on January 31, 2023GlobeNewsWire • 01/30/23
Jasper Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 01/27/23
Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common StockGlobeNewsWire • 01/25/23
Jasper Therapeutics Announces New Positive Briquilimab Data to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTRGlobeNewsWire • 01/13/23
Jasper Therapeutics Announces Development Prioritization of Briquilimab in Chronic Diseases, Including Urticaria and Lower-Risk MDS, and Stem Cell Transplant for Sickle Cell Disease and Other Rare DiseasesGlobeNewsWire • 01/10/23
Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab as a Conditioning Treatment for Patients Prior to Receiving a Stem Cell TransplantGlobeNewsWire • 01/04/23
Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta ThalassemiaGlobeNewsWire • 01/03/23